Skip to main content
Clinical Trials/NCT03088462
NCT03088462
Completed
Not Applicable

LiveWell: A Mobile Intervention for Bipolar Disorder

Northwestern University2 sites in 1 country205 target enrollmentMarch 20, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bipolar Disorder
Sponsor
Northwestern University
Enrollment
205
Locations
2
Primary Endpoint
Longitudinal Interval Follow-up Evaluation-Clinical Monitoring Form: Clinical Status
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

LiveWell is a study evaluating the use of smartphones to better understand and improve the treatment of bipolar disorder. Our goal is to increase access to psychosocial interventions and improve their effectiveness in reducing symptoms and preventing mood episodes.

Detailed Description

A single blind, randomized controlled trial (N = 200, 2:3 ratio of usual care vs usual care and intervention) will be conducted in clinical practices around Chicago and Minneapolis. Eligible participants are adult bipolar 1 disorder patients not experiencing a current mood episode with a history of at least one acute episode in the last two years who are in treatment with a psychiatrist. The primary clinical outcome will be time to relapse, and the secondary outcomes will be percent time symptomatic, symptom severity, and quality of life. Participation in the study lasts for 12 months. Participants are asked to carry a smartphone with them whenever they leave home and wear a wristwatch for measuring activity all day every day. Participants are also asked to complete a series of telephone assessments and may be asked to complete daily check-ins on a smartphone and work with a health coach. Participants will need to attend two in-person clinic visits at 680 N Lake Shore Drive, Chicago IL 60611 Suite 1520 or at 3311 E Old Shakopee Rd, Bloomington, MN 55425.

Registry
clinicaltrials.gov
Start Date
March 20, 2017
End Date
April 10, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Evan Goulding

Assistant Professor, Department of Psychiatry and Behavioral Sciences

Northwestern University

Eligibility Criteria

Inclusion Criteria

  • Adults 18-65 years
  • Bipolar Disorder Type I
  • Minimum of 1 acute episode in the last 2 years

Exclusion Criteria

  • Not receiving psychiatric care
  • Current mood episode
  • Current substance use disorder (within the last 3 months)
  • Current severe suicidal ideation or a recent serious suicide attempt (within the last 3 months)
  • Inability to speak and read English
  • Visual, hearing, voice, cognitive or motor impairment that would prevent completion of study and treatment procedures
  • Participants will need to attend two in-person clinic visits at 680 N Lake Shore Drive, Chicago IL 60611 Suite 1520 or at 3311 E Old Shakopee Rd, Bloomington, MN 55425.

Outcomes

Primary Outcomes

Longitudinal Interval Follow-up Evaluation-Clinical Monitoring Form: Clinical Status

Time Frame: Up to 48 weeks

Semi-structured interview designed to assess clinical status allowing determination of time to relapse (onset of a mood episode). Clinical Status: episode = depression, mania, hypomania, mixed; continued symptomatic (≥ 3 moderate symptoms without recovery), recovering (≤ 2 moderate symptoms, ≤ 8 weeks), prodromal (≥ 3 moderate symptoms after recovery); recovered (≤ 2 moderate symptoms, ≥ 8 weeks).

Secondary Outcomes

  • Change in World Health Organization Quality of Life Scale (BREF)(At 0, 24 and 48 weeks)
  • Longitudinal Interval Follow-up Evaluation-Clinical Monitoring Form: Symptom Severity(48 weeks)
  • Change in Quick Inventory of Depressive Symptomatology-Clinician Rating(At 0, 8, 16, 24, 32, 40 and 48 weeks)
  • Change in Young Mania Rating Scale(At 0, 8, 16, 24, 32, 40 and 48 weeks)

Study Sites (2)

Loading locations...

Similar Trials